Leerink Partners Reiterates Buy Rating on Ionis Pharmaceuticals
Leerink Partners reaffirms its buy rating on Ionis Pharmaceuticals with a $122 price target.
Key Points
- On June 17, 2026, Leerink Partners reiterated its buy rating on Ionis Pharmaceuticals, Inc. (IONS) with a price target of $122.
- Ionis Pharmaceuticals trades at $73.09 with a market cap of about $12.08 billion, a 52-week range of $36.11 to $86.74, and a forward P/E of -98.27.
- Insider transactions include Berthelsen Spencer buying and selling 8,000 shares on June 15, 2026, and Holly Kordasiewicz selling 60,846 shares on June 12, 2026.
Important disclosure: EarningsIQ is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 17, 2026, Leerink Partners reiterated its buy rating on Ionis Pharmaceuticals, Inc. (NasdaqGS: IONS), maintaining a price target of $122. This reflects continued confidence in the company's growth prospects. The stock recently traded around $73.09.
Ionis Pharmaceuticals, Inc. Stock Down 0.3%
Shares of NasdaqGS:IONS are trading near $73.09. Ionis Pharmaceuticals has a market cap of about $12.08 billion and a forward P/E ratio of -98.27, indicating it is not currently profitable. The stock's 52-week range is between $36.11 and $86.74. It has a 50-day moving average of $74.90 and a 200-day moving average of $74.76. The company has a current ratio of 4.10 and a quick ratio of 2.86, with a debt-to-equity ratio of 531.05.
Recent Earnings
Ionis Pharmaceuticals reported revenue of approximately $1.06 billion with a revenue growth of 0.87%. The company had a net margin of -30.9% and a return on equity of -67.6%. The next earnings report is expected on August 5, 2026.
Insider Buying and Selling at Ionis Pharmaceuticals, Inc.
On June 15, 2026, insider Berthelsen Spencer bought 8,000 shares at an average price of $24.42 and sold 8,000 shares at $73.49, with some transactions planned. On June 12, 2026, Holly Kordasiewicz, EVP and Chief Development Officer, sold 60,846 shares at an average price of $73.40 in a planned transaction.
Analysts Set New Price Targets
On June 17, 2026, Leerink Partners maintained its buy rating on Ionis Pharmaceuticals with a $122 price target. Other analysts have also been bullish, with Citigroup initiating coverage with a buy rating and a $115 target on May 19, 2026. RBC Capital, Barclays, and HC Wainwright & Co. have maintained buy ratings with targets of $100, $115, and $125, respectively.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California. The company focuses on developing RNA-targeted medicines. Ionis offers treatments for conditions such as familial chylomicronemia syndrome, hereditary angioedema, and spinal muscular atrophy. It also collaborates with major pharmaceutical companies like Biogen and AstraZeneca.
Bottom Line
Ionis Pharmaceuticals continues to be a focus for analysts, with Leerink Partners reiterating a buy rating and setting a $122 price target. Investors often track these ratings for insights into potential stock performance. Note that these are backward-looking analyses and may not reflect current market conditions.
Get Ionis Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $IONS, sent to your inbox. Free, and you can unsubscribe anytime.
Related Filing Alerts
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.
S